The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Multiple Sclerosis Journal |
| Vol/bind | 28 |
| Udgave nummer | 9 |
| Sider (fra-til) | 1424-1456 |
| Antal sider | 33 |
| ISSN | 1352-4585 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
45. H.W. receives honoraria for acting as a member of Scientific Advisory Boards Biogen, Genzyme, Merck Serono, Novartis, Roche Pharma AG, and Sanofi Aventis, UCB as well as speaker honoraria and travel support from Alexion, Biogen, Biologix, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Merck, Novartis, Roche Pharma AG, Genzyme, TEVA, and WebMD Global. Professor H.W. is acting as a paid consultant for Actelion, Argenx, Biogen, Bristol Myers Squibb, EMD Serono, Idorsia, IGES, Immunic, Immunovant, Janssen, Johnson & Johnson, Novartis, Roche, Sanofi, the Swiss Multiple Sclerosis Society, and UCB and research funding by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and Biogen, GlaxoSmithKline, Roche Pharma AG, Sanofi Genzyme, outside the submitted work.
Funding Information:
8. M.M. has been supported by the National Science Centre Poland grant no. 2020/01/0/NZ6/00072.
Funding Information:
43. S.V. received grants, personal fees, and non-financial support from Biogen, grants and personal fees from Celgene, grants, personal fees, and non-financial support from Genzyme, grants, personal fees and non-financial support from Merck Serono, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Roche, grants, personal fees, and non-financial support from Sanofi.
Funding Information:
5. T.D. serves on scientific advisory boards for Novartis, Merck, Biogen, Genzyme, GeNeuro, Mitsubishi Pharma, Actelion, Roche, Alexion, and Celgene; has received funding for travel and/or speaker honoraria from Biogen, Genzyme, Novartis, Merck, and Roche; and received research support from Alexion, Biogen, Novartis, Roche, the European Union, the Swiss National Science Foundation, and the Swiss MS Society.
Funding Information:
1. C.T. is currently being funded by a Junior Leader La Caixa Fellowship (fellowship code is LCF/BQ/PI20/11760008), awarded by “la Caixa” Foundation (ID 100010434). She has also received the 2021 Merck’s Award for the Investigation in MS, awarded by Fundación Merck Salud (Spain). In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She has also received honoraria from Roche and Novartis, and is a steering committee member of the of the O’HAND trial and of the Consensus group on Follow-on DMTs. She is a member of the Editorial Boards of Neurology and Multiple Sclerosis Journal. Dr C.T. has no disclosures related to this work.
Funding Information:
40. M.P.S. has received consulting fees and research grants from Biogen, Roche, Novartis, Sanofi, Merck, GSK, Immunic, and GeNeuro.
Funding Information:
38. A.S. has received honoraria or consultancy fees for participating to advisory boards, giving educational lectures and/or travel and registration coverage for attending scientific congresses or symposia from F. Hoffmann-La Roche Ltd., Sanofi Genzyme, Merck Serono, Novartis, Teva, Biogen Idec/Gen Pharma of Turkey, and Abdi İbrahim İlaç. He reports getting research grants from Istanbul University Research Support Grants, and from The Scientific and Technological Research Council Of Turkey—Health Sciences Research Grants. Dr A.S. has no disclosures related to this work.
Funding Information:
41. M.T. has received compensation for consulting from Biogen, Genzyme, Merck Serono, Novartis, and Roche and speaker honoraria from Biogen, Genzyme, Merck Serono, Novartis, Sanofi, and Teva, and her institution has received research grants from Biogen, Merck Serono, and Novartis.
Funding Information:
6. F.D.P. has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations), or travel funding from Bayer, Biogen, Celgene, Merck, Novartis, Sanofi Genzyme, Roche, and Teva.
Publisher Copyright:
© The Author(s), 2022.
ID: 325462179